It looks like we're about at the peak of the Delta SARS-CoV-2 wave in the US (figure based on @CDCGov data). A thread on current circulation patterns and the impact of Delta. 1/14
This inflection point in case loads at the country-level is due to decline in some states (such as FL and LA) and growth in others (such as OH and WV). Figure shows cases per 100k population on a log axis to emphasis state-level growth and decline. 2/14
Using previously described method to split cases by variant frequency (
), we see a striking pattern in which most states have a moderate spring wave comprised of a mix of Alpha and other variants, but show a large Delta wave in the summer. 3/14
If we take the starting point for the US Delta wave at June 15th, we have a cumulative ~6.4M cases between Jun 15 and Sep 3, and if we assume 2.7 infections per reported case (
), we arrive at ~17.3M infections up to this point during the Delta wave. 4/14
Assuming there are approximately another 17.3M infections on the other side of the Delta peak (which may not be the case), we arrive at roughly 34.6M Delta infections in the US wave, which is pretty close to my forecast ~36M infections on June 30. 5/14
Globally, we see that Delta is nearly dominant everywhere in the world except South America (nextstrain.org/ncov/gisaid/gl… showing distribution of samples from July 1). 6/14
Delta appears competitive with endogenous South American variants Gamma, Lambda and Mu (nextstrain.org/ncov/gisaid/so…) and I expect it will displace existing variation in the comings weeks. 7/14
This suggests that it will only take roughly 1 year for the emergence of Delta in late 2020 to (near) fixation in the global SARS-CoV-2 viral population. This "selective sweep" is extremely rapid commensurate with Delta's large jump in viral fitness. 8/14
In comparison, seasonal influenza H3N2 sees new strains appear and take 2-5 years to sweep through the global viral population (bedford.io/papers/bedford…). Having a new SARS-CoV-2 variant sweep in ~1 year is remarkable, especially given continued reductions in global travel. 9/14
Although PANGO has designated sub-lineages AY.1 to AY.25 of B.1.617.2 (Delta), this has been for purposes of epidemiological tracking (pango.network/new-ay-lineage…) and so far no striking sub-lineages of Delta have emerged. 10/14
However, there is a split in Delta diversity with one sub-clade bearing ORF1a mutations L1640P, P2287S, V2930L (among others) and the other bearing ORF1a A3209V (nextstrain.org/ncov/gisaid/gl…). The sub-clade with ORF1a L1640P et al is gaining in frequency, but pace has been slow. 11/14
At this point, it seems highly likely that the next impactful variant will emerge as a sub-lineage from within Delta diversity, bearing additional mutations on top of Delta's mutations. Consequently, I would urge that the regulatory process for vaccine updates begin. 12/14
Although Delta has had relatively small impacts on neutralization titers (perhaps 6-8X reductions) and vaccine effectiveness (perhaps 10-20% reductions), with a newly reduced viral diversity, a vaccine update to a basal Delta virus seems like an easy win. 13/14
Even if current impact of Delta on vaccine effectiveness is minor, updating the vaccine strain should provide a buffer against further viral evolution relative to continuing with a Wuhan-like vaccine strain. 14/14
Follow up #1: Replies have questioned the statement about this being the "peak" of the Delta wave (like
). Fundamentally, what's going on is this: the large Delta wave has immunized a fraction of the US population (roughly 5% so far) on top of vaccination.
Follow up #2: Current population immunity + current behavior results in Rt of ~1. Vaccination and Delta imposed immunity will continue and further reduce Rt, while school term forcing, seasonality and waning immunity will act to increase Rt.
Follow up #3: I would guess that school term forcing won't be enough to flip Rt above 1, but school term + seasonality + waning may well be enough to do so. This would suggest case loads picking up again later in the fall, but I'd expect some decrease in the intervening weeks.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New (not yet peer-reviewed) work by Katie Kistler and @huddlej in the lab assessing adaptive evolution in SARS-CoV-2 across the viral genome. 1/12 biorxiv.org/content/10.110…
We measure adaptive evolution by correlating mutations in different regions of the genome with growth of clade frequency. For this, we use a viral phylogeny of ~10k genomes sampled equitably through space and time across the pandemic (nextstrain.org/groups/blab/nc…). 2/12
If mutations to a region result in fitter viruses, clades bearing these mutations should expand more rapidly. We find that the S1 domain of spike accumulates protein-coding (nonsynonymous) changes rapidly and that clades with more S1 mutations tend to grow in frequency. 3/12
I'm not an immunologist, but I've been trying to read into the literature on waning immunity to SARS-CoV-2 and to understand the recent NIH, CDC, FDA booster recommendation (hhs.gov/about/news/202…). I'll share some takeaways here. 1/14
Previous studies in other viruses found that the potency and the concentration of circulating antibodies in an individual is often predictive of their protection to infection or illness after exposure. 2/14
This potency + concentration is commonly quantified as the titer required to neutralize 50% of viral plaques in a lab assay. These assays are run by diluting sera from an individual and seeing what dilution causes loss of neutralization. 3/14
How big of a wave of #COVID19 do we expect in the US from the Delta variant? Here I describe a simple approach to this question and attempt a rough back-of-the-envelop estimate. 1/16
First off, epidemic size is determined by two primary factors: 1. Efficiency of onward transmission from an index case, commonly quantified as R0 2. Size of susceptible pool
2/16
Given a specified R0, we can calculate final epidemic size in a simple SIR model with the following equation where Z is final epidemic size. For initial R0 of 1.1, an epidemic is expected to infect 18% of the susceptible population. 3/16
Jesse Bloom's preprint has, of course, caused quite a stir. I wanted to try to explain a bit about the "rooting issue" discussed in the manuscript and also provide some hopefully clarifying phylogenetic trees. 1/15
For this post, I've made a @nextstrain "build" targeted at SARS-CoV-2 genomes from Dec 2019 through Jan 2020, totaling 549 viruses. All code is here: github.com/blab/ncov-earl… and should be reproducible using a download of @GISAID data. 2/15
There is genetic diversity within these very early samples with much of it arising from a split in early transmission chains into lineage A and lineage B viruses (lineage B as in B.1.1.7). Lineage A and lineage B viruses are separated by mutations at sites 8782 and 28144. 3/15
An update on genomic surveillance in the US and spread of the Delta variant (PANGO lineage B.1.617.2, Nextstrain clade 21A). At this point, 95% of viruses circulating in the US are "variant" viruses that have been designated as "Variant of Concern" or "Variant of Interest". 1/12
This update mirrors how I was looking at the rise of P.1 across the US in May. 2/12
Here, we can look at frequencies of different variant lineages through time and across states where it's clear that variant viruses and in particular B.1.617.2 viruses are continuing to increase in frequency. 3/12
With the publication of the Science letter, the Overton window for discussion of "lab leak" hypothesis has shifted dramatically. We now have mainstream scientific opinions that largely range between "lab leak can be dismissed" and "both zoonosis and lab leak are viable". 1/8
I am in the both are plausible camp. The data (as it exists) is consistent with zoonosis, but it's also consistent with lab leak. Parsing the relative probabilities of the two depends on multiple lines of evidence and is necessarily assumption ridden. 2/8
However, I think that there is a philosophical divide among scientists in how to assess hypotheses that perhaps explains some of the gap in opinion. Ie, is zoonosis the "null" hypothesis that we need significant evidence to reject or are we comparing two competing hypotheses? 3/8